EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial

Toshimasa Yamauchi iD, Taro Asakura, Tomotaka Shingaki iD, Tomonori Oura iD, Hideki Katagiri iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16500 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Toshimasa Yamauchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Overweight, Anti-Obesity Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the efficacy and safety of once‐weekly tirzepatide in Japanese participants with obesity and type 2 diabetes (T2D). Materials and Methods This subpopulation analysis of 41 Japanese participants from three clinical trial sites in the SURMOUNT‐2 trial evaluated the efficacy and safety of tirzepatide as an adjunct to lifestyle interventions in adults with body mass index ≥27 kg/m 2 and a diagnosis of T2D with glycated haemoglobin ≥7% to ≤10%. Coprimary endpoints were mean percent change in body weight and proportion of participants who achieved ≥5% body weight reduction at week 72. Percent change in body weight was compared between tirzepatide and placebo using a mixed model for repeated measures.

Results

The mean percent change (standard error) in body weight from baseline to week 72 was statistically significantly greater for both tirzepatide 10 mg ( p = 0.001) and 15 mg ( p = 0.013) compared with placebo: −12.4% (1.8%) and −10.2% (1.8%), respectively, compared with −3.5% (1.8%). At week 72, 85.7% and 78.6% of participants in the tirzepatide 10 mg and 15 mg groups, respectively, had a body weight reduction of ≥5%, versus 46.2% of participants receiving placebo. Reductions in glycemic parameters, waist circumference and systolic blood pressure, as well as numerical improvements in the lipid profile, were also observed with tirzepatide. No new safety concerns were identified.

Conclusions

In Japanese adults with obesity and T2D, once‐weekly treatment with tirzepatide (10 or 15 mg) demonstrated significant reductions in body weight compared with placebo, with the safety profile generally consistent with previous studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityOverweightAnti-Obesity AgentsHypoglycemic AgentsHumansFemaleMaleMiddle AgedJapanTirzepatideTreatment OutcomeWeight LossAgedGlycated HemoglobinDouble-Blind MethodBody Mass IndexDrug Administration ScheduleAdultBlood GlucoseEast Asian People

Stichwörter der Autor:innen

Japanobesitytirzepatidetype 2 diabetes

Substanzen

TirzepatideGlycated HemoglobinBlood GlucoseAnti-Obesity AgentsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic, Yamato, Japan.
  • Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.
  • Department of Diabetes, Metabolism and Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Toshimasa Yamauchi, Tomotaka Shingaki, Tomonori Oura, Hideki Katagiri

Förderung

  • Eli Lilly and Company

Zitieren

APA

Yamauchi, T., Asakura, T., Shingaki, T., Oura, T., & Katagiri, H. (2025). Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16500

Vancouver

Yamauchi T, Asakura T, Shingaki T, Oura T, Katagiri H. Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16500

BibTeX
@article{Yamauchi2025,
  author = {Yamauchi, Toshimasa and Asakura, Taro and Shingaki, Tomotaka and Oura, Tomonori and Katagiri, Hideki},
  title = {Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16500}
}
Kostenlos starten →